Sharemaestro Newsreel

Perrigo Company plc (PRGO) Stock Forecasts

This article provides an analyst report from Morningstar on Perrigo Company plc (PRGO), a consumer healthcare product manufacturer. The report highlights the company's recent infant formula recovery, which was met with excitement despite ongoing uncertainties. Perrigo specializes in private-label consumer health goods sold through …

Perrigo Company Plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Perrigo Company Plc recently exceeded its earnings expectations. This article will discuss what analysts anticipate for the company's future performance following this positive earnings report.

Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts

Argus has lowered its target price for Supernus Pharmaceuticals Inc. (SUPN) to $41.00, while the current stock price is $47.64. Supernus Pharmaceuticals specializes in developing and commercializing treatments for central nervous system diseases. Investors can access the full report with a Yahoo Finance Silver …

Results: Perrigo Company plc Exceeded Expectations And The Consensus Has Updated Its Estimates

Perrigo Company plc (NYSE:PRGO) shareholders saw a 27% increase in their stake following better-than-expected quarterly profits, despite revenues meeting analyst forecasts. While analysts reconfirmed revenue estimates for 2026, they significantly increased per-share loss predictions, though the consensus price target remained unchanged at US$16.50. The …

Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $20.00 by Analysts at Piper Sandler

Piper Sandler has reduced its price target for Amphastar Pharmaceuticals (AMPH) to $20.00 from $21.00, maintaining a "neutral" rating despite the company's recent earnings beat. While Amphastar exceeded analyst expectations with adjusted EPS of $0.91 and revenue of $183.9 million, overall analyst sentiment remains …

Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Zacks Research

Zacks Research has upgraded Supernus Pharmaceuticals (NASDAQ:SUPN) from a "hold" to a "strong-buy" rating. This upgrade comes despite a broader analyst consensus of "Moderate Buy" with a target price of $62.83. The company, which specializes in central nervous system therapies, also saw several institutional …

Should FDA Approval of ORZEYFUL for Narcolepsy Type 1 Prompt Action From Takeda Pharmaceutical (TSE:4502) Investors?

The FDA recently approved Takeda Pharmaceutical's ORZEYFUL for narcolepsy type 1, providing a new entry into a rare disease market addressing orexin deficiency. While this approval strengthens Takeda's pipeline narrative, management has indicated it won't significantly alter this year's financial forecast. Investors should focus …

Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Leerink Partners to "Market Perform"

Leerink Partners has downgraded Akebia Therapeutics (NASDAQ:AKBA) from "Outperform" to "Market Perform," setting a new price target of $1.00. This downgrade implies a potential upside of 4.78% from its previous close. Despite beating quarterly EPS and revenue estimates, Akebia's shares fell 26%, opening at …

Akebia Therapeutics (AKBA) AGM 2026 Summary

This article summarizes Akebia Therapeutics' (AKBA) 2026 Annual General Meeting (AGM), detailing the agenda, including the election of Class III directors, approval of an increase in authorized capital, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the …

Xeris Biopharma Holdings Inc (XERS) Stock News Today

This article provides current stock information for Xeris Biopharma Holdings Inc (XERS) including its recent closing price, market capitalization, and P/E ratio. It highlights that the company's stock experienced a gain of 7.74% and indicates that more news and earnings updates are expected soon …

Zoetis Earnings: Full Force of Heightened Competition on Display; Cutting Our Fair Value Estimate

Zoetis reported flat top-line growth and a 5% decline in earnings year over year for its second quarter, primarily due to an 11% drop in US companion animal revenue. Consequently, the company significantly reduced its revenue and earnings per share guidance. Morningstar has lowered …

Aurora Cannabis (NASDAQ:ACB) Upgraded by BMO Capital Markets to Hold Rating

BMO Capital Markets has upgraded Aurora Cannabis (NASDAQ:ACB) to a "hold" rating. The company recently reported quarterly EPS of $0.07, exceeding expectations for a $0.07 loss, and revenue of $60.98 million, surpassing the $54.42 million consensus estimate, though it remained unprofitable. Aurora Cannabis currently …

Alpha Teknova (NASDAQ:TKNO) Raised to Hold at Zacks Research

Zacks Research has upgraded Alpha Teknova (NASDAQ:TKNO) to a "hold" rating, contributing to a mixed analyst consensus for the stock. While the company's recent quarterly results surpassed revenue and EPS expectations, it continues to face profitability challenges with negative net margins. Institutional ownership remains …

Zoetis Cut Its 2026 Guide in Q2 Earnings. The Dermatology Lead Is the Reason.

Why Rescheduling Might Not Move Canopy Growth's Stock as Much as You Think

Key Points The United States is slowly moving toward the legalization of marijuana. The next big step is the rescheduling of the drug at the federal level, which won't make it legal, just less illegal. Canopy Growth's business won't be dramatically impacted either way.10 …

Liquidia Corporation (LQDA) Stock Forecasts

Liquidia Corp (LQDA) has received an Investment Rating of HOLD from Argus, with a target price raised to $93.00. The report details subratings for various financial aspects, categorizing the company's financial strength, growth, and value. Users can upgrade to premium services to access the …

Perrigo (PRGO) In Focus As Q2 Earnings Beat Revives The Undervalued Narrative

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Why Perrigo Stock Is Back in Focus After Q2 Earnings Perrigo (PRGO) is drawing fresh attention after second quarter 2026 adjusted earnings per share came in ahead …

Fierce Pharma Asia—Takeda’s historic narcolepsy nod; Daiichi’s accounting error; Astellas’ revenue beat

This Fierce Pharma Asia update covers several key developments in the pharmaceutical industry. Takeda received FDA approval for Orzeyful, a first-in-class narcolepsy treatment, while Daiichi Sankyo's shares dropped due to a disclosed accounting error despite strong revenue. Astellas reported record quarterly revenue driven by …

Lantheus Holdings, Inc. $LNTH is Reinhart Partners LLC.'s 2nd Largest Position

Reinhart Partners LLC. has increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.2%, making it their second-largest holding and comprising 4.1% of their portfolio. Despite this, analyst sentiment has softened, leading to several downgrades to "Hold" and a consensus price target of $108.11. …

Optimi Health Corp. (OPTH) investor reports 8.25% beneficial stake via Cathay Visions

Cathay Visions Enterprises Inc. and its sole owner, Dane Nicholas Stevens, have reported an 8.25% beneficial ownership stake in Optimi Health Corp. (OPTH) through a Schedule 13G filing. This holding comprises 456,347 common shares and options/warrants exercisable for an additional 17,777 common shares, totaling …

Optimi Health (OPTH) CEO adds 3,800 shares at CDN$6.70

Optimi Health Corp.'s CEO, Dane Stevens, purchased 3,800 common shares at CDN$6.70 per share on August 5, 2026, through Cathay Visions Enterprises Ltd. This open market transaction increases his beneficial ownership to 456,347 common shares. The insider trade was disclosed in a Form 6-K …

Incannex Healthcare Inc (IXHL) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Incannex Healthcare Inc (IXHL), detailing its current price momentum, support and resistance levels, and various technical indicators. It shows that IXHL is currently trading between a resistance level of 3.46 and a support level of 2.84, suggesting …

Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive information on Teva Pharmaceutical Industries Limited (TEVA), including its current stock price, news headlines, and historical performance data. The stock closed at $35.36, up 1.58% on August 7, and traded slightly down in after-hours. The news section highlights …

Prestige Consumer Healthcare Inc. $PBH Shares Bought by First Trust Advisors LP

First Trust Advisors LP significantly increased its stake in Prestige Consumer Healthcare Inc. (PBH) by 137.5% in the first quarter, now owning 37,395 shares valued at approximately $2.2 million. The company exceeded quarterly expectations with adjusted EPS of $0.98 and revenue of $265.7 million, …

Siga Technologies Q2 Earnings Call Highlights

Siga Technologies reported $38 million in Q2 product revenue, driven by TPOXX sales to the U.S. Strategic National Stockpile and international customers, resulting in a net income of $12 million. The company is in ongoing discussions for a new multiyear TPOXX procurement agreement with …

Should Xeris Biopharma Holdings (XERS) Be Revalued After Strong Q2 Revenue And Fresh Guidance?

Xeris Biopharma Holdings (XERS) is attracting investor attention following its Q2 earnings report, which included strong performance and a refined full-year 2026 revenue outlook. The stock is currently trading at $7.93, with a recent 7.74% one-day return, and analysts consider it undervalued with a …

Evolus Inc (EOLS) Stock News Today

This page provides an overview of Evolus Inc (EOLS) stock news, earnings, analyst ratings, and key developments. It notes the current stock price, market cap, and indicates that more news will be coming soon. The page serves as a hub for investors to track …

Hims & Hers Health (HIMS) Responds To FTC Lawsuit Over Patient Data Use

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Hims & Hers Health (NYSE:HIMS) has issued a public response to a Federal Trade Commission lawsuit that challenges aspects of its telehealth practices …

Evotec AG (NASDAQ:EVO) Receives Consensus Recommendation of "Hold" from Brokerages

Evotec AG (NASDAQ:EVO) has received a consensus "Hold" recommendation from five brokerages, with an average 12-month price target of $3.00. The ratings include two "Buy," two "Hold," and one "Sell," reflecting cautious sentiment. Recent analyst actions have shown mixed views, with some downgrades and …

SCYNEXis Inc (SCYX) Stock News Today

This article provides current stock news for SCYNEXIS Inc (SCYX) from TradingKey. It displays the latest stock price, market cap, and links to various financial data and analysis sections for the company. The article notes that more news is coming soon for SCYX.

Tilray Brands, Inc. (NASDAQ:TLRY) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Analysts have given Tilray Brands, Inc. (NASDAQ:TLRY) a "Moderate Buy" consensus rating, with an average 12-month price target of $11.00 compared to its recent opening price of $4.57. Despite beating revenue estimates with $281.71 million, the company missed EPS expectations, reporting a negative $0.43 …

Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers

Cetera Investment Advisers significantly increased its stake in Neurocrine Biosciences (NBIX) by 50.1% in the first quarter, now owning 20,245 shares valued at $2.67 million. Institutional investors hold 92.59% of NBIX. Despite insider sales totaling over $62 million in the past quarter, analysts maintain …

Assenagon Asset Management S.A. Grows Position in Teva Pharmaceutical Industries Ltd. $TEVA

Assenagon Asset Management S.A. significantly increased its stake in Teva Pharmaceutical Industries Ltd. by 128.1% in the second quarter, now holding over 3 million shares valued at approximately $103.5 million. Institutional investors collectively own 54.05% of Teva, and analysts maintain a "Moderate Buy" rating …

Dimensional Fund Advisors LP Raises Position in Bausch Health Cos Inc. $BHC

Dimensional Fund Advisors LP significantly increased its stake in Bausch Health Cos Inc. by 10.8% in the first quarter of 2026, acquiring 350,823 additional shares to reach a total of 3.6 million shares. Other institutional investors also raised their positions, with institutions now owning …

ANI Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ANIP) 2026-08-08

ANI Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Transformation and Operational Execution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Canopy Growth posts 13% revenue rise and narrows losses in Q1 fiscal 2027, shares up 5%.

Canopy Growth Corporation reported a 13% increase in net revenue to C$81.2 million for the first quarter of fiscal 2027, exceeding analyst estimates. The company significantly narrowed its adjusted EBITDA losses by 59% to C$3.2 million and reduced its net loss by 68% year-over-year. …